Rivaroxaban效果怎么样？

Rivaroxaban was jointly developed by Bayer Pharmaceuticals of Germany and Johnson & Johnson of the United States. It is suitable for:

1. For adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. For use in adult patients with non-valvular atrial fibrillation who have one or more risk factors (such as congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

How effective is Rivaroxaban?

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets.

A dose-dependent inhibition of factor Xa activity by Rivaroxaban has been observed in humans. Rivaroxaban's effect on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents. Reading the PT should be completed within seconds because the International Normalized Ratio (INR) is calibrated and validated only for coumarins and not for other anticoagulants.

In patients undergoing major orthopedic surgery, 5/95th (percentile) PT was (NeopLastin) 13-25 seconds 2-4 hours after taking Rivaroxaban (when the effect is strongest) (baseline before surgery was 12-15 seconds).